Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis

— Gannex is expected to release topline data of the Phase II clinical trial by the end of 2023 SHANGHAI, July 19, 2023 /PRNewswire/ — Gannex Pharma Co., Ltd. (“Gannex”), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today the completion of enrollment of 98…